Session » SLE – Treatment Poster I

Date: Saturday, November 16, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 0670

A Randomized, Open-Label, Phase III Trial Comparing Efficacy and Safety of Intravenous Cyclophosphamide, Mycophenolate Mofetil, or Tacrolimus as Induction Therapy in Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 0673

BCMA-CD19 Compound CAR-T (cCAR) Safely Provides a Complete Humoral Reset Eliminating All Autoantibodies Resulting in Long-term Medication-Free Complete Remission Among Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients

10:30AM-12:30PM: Abstract Number: 0665

Belimumab Induces Early and Sustained Resolution of Lupus Thrombocytopenia and Lupus Arthritis

10:30AM-12:30PM: Abstract Number: 0662

Deucravacitinib, a First-in-Class, Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in SLE: Efficacy by Baseline Demographics and Disease Characteristics in the Phase 2 PAISLEY Trial

10:30AM-12:30PM: Abstract Number: 0667

Early Introduction of Biologic Agents in Systemic Lupus Erythematosus Reduces Relapse and Glucocorticoid Maintenance Dose: A Cohort Study from the PLEAJURE J Registry

10:30AM-12:30PM: Abstract Number: 0671

Effect of Litifilimab on Cutaneous Lupus Erythematosus Disease Area and Severity Index–Activity (CLASI-A) Subcomponents and Physician Global Assessment–Skin (PGA–Skin) in Patients with Cutaneous Lupus Erythematosus (CLE) in a Phase 2 Study

10:30AM-12:30PM: Abstract Number: 0669

Efficacy of Belimumab in Systemic Lupus Erythematosus: A Single-Centre Retrospective Study

10:30AM-12:30PM: Abstract Number: 0675

Hydroxychloroquine Induced Cardiomyopathy: A Biopsy Proven Case Series

10:30AM-12:30PM: Abstract Number: 0674

Hydroxychloroquine Screening Adherence: Insights from Highmark Claims Data

10:30AM-12:30PM: Abstract Number: 0660

Hydroxychloroquine Users at Lower Risk of Kidney Function Decline in Lupus Nephritis

10:30AM-12:30PM: Abstract Number: 0664

Impact of Hydroxychloroquine and Belimumab on Early Glucocorticoid Reduction in New-Onset Systemic Lupus Erythematosus: A Retrospective Analysis of Risk and Protective Factors

10:30AM-12:30PM: Abstract Number: 0666

Interferon-stimulated Genes on Peripheral CD8+ T Cells of SLE Patients Were the Keys for Early Response to BAFF/APRIL-targeted Therapy

10:30AM-12:30PM: Abstract Number: 0659

Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial

10:30AM-12:30PM: Abstract Number: 0672

Pharmacokinetics (PK), Effectiveness and Safety of Open-label (OL) Tofacitinib for the Treatment of Moderate to Severe Skin Involvement in Young Adults with SLE

10:30AM-12:30PM: Abstract Number: 0668

There Are No Shortcuts: Electronic Health Record-Generated Tool Does Not Reflect Medication Adherence in Patients with SLEin Bronx, NY

10:30AM-12:30PM: Abstract Number: 0663

Treatment Patterns and the Prevalence of Kidney Biopsy-Confirmed LN in Patients with SLE and Proteinuria: A Multicenter Cohort Study

10:30AM-12:30PM: Abstract Number: 0676

Understanding the Patient Burden of Lupus: Insights from Multi-Faceted Ethnography Research

10:30AM-12:30PM: Abstract Number: 0661

Validity, Reliability and Responsiveness of Lupus Impact Tracker and LupusPRO: AURORA Trial

10:30AM-12:30PM: Abstract Number: 0658

Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor, Demonstrated Improvements in SLE/LN Disease Measures and Biomarkers in Patients with Highly Active SLE or Nephrotic Range Proteinuria in the Open-label Phase 1b/2 MISSION Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].